172 related articles for article (PubMed ID: 21852906)
1. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
Shin JE; Choi HJ; Kim MH; Cho KS
Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors.
Xiao F; Zhang L; Yang S; Peng K; Hua T; Tang G
J Ovarian Res; 2022 Jan; 15(1):13. PubMed ID: 35062992
[TBL] [Abstract][Full Text] [Related]
4. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
5. Computed Tomography Indicators for Differentiating Stage 1 Borderline Ovarian Tumors from Stage I Malignant Epithelial Ovarian Tumors.
Moon MH; Park HS; Kim YJ; Yu MH; Park S; Jung SI
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766584
[TBL] [Abstract][Full Text] [Related]
6. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MRI for differentiation of borderline ovarian tumors from stage I malignant epithelial ovarian tumors using multivariate logistic regression analysis.
Denewar FA; Takeuchi M; Urano M; Kamishima Y; Kawai T; Takahashi N; Takeuchi M; Kobayashi S; Honda J; Shibamoto Y
Eur J Radiol; 2017 Jun; 91():116-123. PubMed ID: 28629557
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
[TBL] [Abstract][Full Text] [Related]
10. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
11. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.
Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917
[TBL] [Abstract][Full Text] [Related]
12. Texture Analysis of Three-Dimensional MRI Images May Differentiate Borderline and Malignant Epithelial Ovarian Tumors.
Ye R; Weng S; Li Y; Yan C; Chen J; Zhu Y; Wen L
Korean J Radiol; 2021 Jan; 22(1):106-117. PubMed ID: 32932563
[TBL] [Abstract][Full Text] [Related]
13. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
14. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
15. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
17. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Zhang W; Wang L; Xin Z
Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
[TBL] [Abstract][Full Text] [Related]
18. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
[TBL] [Abstract][Full Text] [Related]
19. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]